Literature DB >> 23175380

An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells.

Thor A Wagner1, Jen L McKernan, Nicole H Tobin, Ken A Tapia, James I Mullins, Lisa M Frenkel.   

Abstract

Understanding how HIV-1 persists during effective antiretroviral therapy (ART) should inform strategies to cure HIV-1 infection. We hypothesize that proliferation of HIV-1-infected cells contributes to persistence of HIV-1 infection during suppressive ART. This predicts that identical or monotypic HIV-1 DNA sequences will increase over time during ART. We analyzed 1,656 env and pol sequences generated following single-genome amplification from the blood and sputum of six individuals during long-term suppressive ART. The median proportion of monotypic sequences increased from 25.0% prior to ART to 43.2% after a median of 9.8 years of suppressive ART. The proportion of monotypic sequences was estimated to increase 3.3% per year (95% confidence interval, 2.3 to 4.4%; P < 0.001). Drug resistance mutations were not more common in the monotypic sequences, arguing against viral replication during times with lower antiretroviral concentrations. Bioinformatic analysis found equivalent genetic distances of monotypic and nonmonotypic sequences from the predicted founder virus sequence, suggesting that the relative increase in monotypic variants over time is not due to selective survival of cells with viruses from the time of acute infection or from just prior to ART initiation. Furthermore, while the total HIV-1 DNA load decreased during ART, the calculated concentration of monotypic sequences was stable in children, despite growth over nearly a decade of observation, consistent with proliferation of infected CD4(+) T cells and slower decay of monotypic sequences. Our findings suggest that proliferation of cells with proviruses is a likely mechanism of HIV-1 DNA persistence, which should be considered when designing strategies to eradicate HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175380      PMCID: PMC3554159          DOI: 10.1128/JVI.01985-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays.

Authors:  A G Rodrigo; P C Goracke; K Rowhanian; J I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  1997-06-10       Impact factor: 2.205

2.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Time to hit HIV, early and hard.

Authors:  D D Ho
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.

Authors:  Deborah Persaud; George K Siberry; Aima Ahonkhai; Joleen Kajdas; Daphne Monie; Nancy Hutton; Douglas C Watson; Thomas C Quinn; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

Authors:  T W Chun; D Finzi; J Margolick; K Chadwick; D Schwartz; R F Siliciano
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  56 in total

1.  Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Authors:  Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

Review 2.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

Review 3.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 4.  Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.

Authors:  Rebecca Rose; David J Nolan; Ekaterina Maidji; Cheryl A Stoddart; Elyse J Singer; Susanna L Lamers; Michael S McGrath
Journal:  AIDS Res Hum Retroviruses       Date:  2017-08-07       Impact factor: 2.205

5.  Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Authors:  Julio C C Lorenzi; Yehuda Z Cohen; Lillian B Cohn; Edward F Kreider; John P Barton; Gerald H Learn; Thiago Oliveira; Christy L Lavine; Joshua A Horwitz; Allison Settler; Mila Jankovic; Michael S Seaman; Arup K Chakraborty; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-21       Impact factor: 11.205

6.  HIV-1 integration landscape during latent and active infection.

Authors:  Lillian B Cohn; Israel T Silva; Thiago Y Oliveira; Rafael A Rosales; Erica H Parrish; Gerald H Learn; Beatrice H Hahn; Julie L Czartoski; M Juliana McElrath; Clara Lehmann; Florian Klein; Marina Caskey; Bruce D Walker; Janet D Siliciano; Robert F Siliciano; Mila Jankovic; Michel C Nussenzweig
Journal:  Cell       Date:  2015-01-29       Impact factor: 41.582

7.  Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells.

Authors:  Natalia Soriano-Sarabia; Rosalie E Bateson; Noelle P Dahl; Amanda M Crooks; JoAnn D Kuruc; David M Margolis; Nancie M Archin
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

Review 8.  Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire.

Authors:  Aaron Christensen-Quick; Christophe Vanpouille; Andrea Lisco; Sara Gianella
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

9.  Epigenetic Metabolite Acetate Inhibits Class I/II Histone Deacetylases, Promotes Histone Acetylation, and Increases HIV-1 Integration in CD4+ T Cells.

Authors:  Jean-François Bolduc; Laurent Hany; Corinne Barat; Michel Ouellet; Michel J Tremblay
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 10.  HIV-1 Reservoirs During Suppressive Therapy.

Authors:  Kirston Barton; Anni Winckelmann; Sarah Palmer
Journal:  Trends Microbiol       Date:  2016-02-12       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.